Cyclacel Pharmaceuticals, Inc. Accounts Receivable, after Allowance for Credit Loss, Current in USD from Q4 2011 to Q3 2025

Taxonomy & unit
us-gaap: USD
Description
Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.
Summary
Cyclacel Pharmaceuticals, Inc. quarterly Accounts Receivable, after Allowance for Credit Loss, Current history and growth rate from Q4 2011 to Q3 2025.
  • Cyclacel Pharmaceuticals, Inc. Accounts Receivable, after Allowance for Credit Loss, Current for the quarter ending September 30, 2025 was $725K.
Accounts Receivable, after Allowance for Credit Loss, Current, Quarterly (USD)
Accounts Receivable, after Allowance for Credit Loss, Current, YoY Quarterly Growth (%)

Cyclacel Pharmaceuticals, Inc. Quarterly Accounts Receivable, after Allowance for Credit Loss, Current (USD)

Period Value YoY Chg Change % Date Report Filed
Q3 2025 $725K Sep 30, 2025 10-Q 2025-11-13
Q2 2018 $66K -$23K -25.8% Jun 30, 2018 10-Q 2018-08-09
Q1 2018 $600K -$279K -31.7% Mar 31, 2018 10-Q 2018-05-14
Q2 2017 $89K Jun 30, 2017 10-Q 2017-08-10
Q1 2017 $879K Mar 31, 2017 10-Q 2017-05-12
Q4 2016 $10K Dec 31, 2016 10-Q 2017-08-10
Q2 2012 $45K Jun 30, 2012 10-Q 2012-08-14
Q4 2011 $116K Dec 31, 2011 10-Q 2012-08-14
* An asterisk sign (*) next to the value indicates that the value is likely invalid.